These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32750756)

  • 1. PD-L1, PDK-1 and p-Akt are correlated in patients with papillary thyroid carcinoma.
    Wang H; Zhang Z; Yan Z; Ma S
    Adv Clin Exp Med; 2020 Jul; 29(7):785-792. PubMed ID: 32750756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
    Shi RL; Qu N; Luo TX; Xiang J; Liao T; Sun GH; Wang Y; Wang YL; Huang CP; Ji QH
    Thyroid; 2017 Apr; 27(4):537-545. PubMed ID: 27825291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis.
    Lubin D; Baraban E; Lisby A; Jalali-Farahani S; Zhang P; Livolsi V
    Endocr Pathol; 2018 Dec; 29(4):317-323. PubMed ID: 30121940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
    Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
    Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma.
    Bai Y; Niu D; Huang X; Jia L; Kang Q; Dou F; Ji X; Xue W; Liu Y; Li Z; Feng Q; Lin D; Kakudo K
    Diagn Pathol; 2017 Oct; 12(1):72. PubMed ID: 28974264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 Expression and Ultrasound Characteristics in Papillary Thyroid Carcinoma and Its Effect on Recurrence.
    Li R; Li M; Sun B; Qi M; Peng C; Li H; Zheng S; Liu Q; Jiang C
    In Vivo; 2023; 37(6):2820-2828. PubMed ID: 37905619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma.
    Girolami I; Pantanowitz L; Mete O; Brunelli M; Marletta S; Colato C; Trimboli P; Crescenzi A; Bongiovanni M; Barbareschi M; Eccher A
    Endocr Pathol; 2020 Sep; 31(3):291-300. PubMed ID: 32468210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related.
    Bai Y; Guo T; Huang X; Wu Q; Niu D; Ji X; Feng Q; Li Z; Kakudo K
    Virchows Arch; 2018 May; 472(5):779-787. PubMed ID: 29651624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 and B7-H3 are Effective Prognostic Factors and Potential Therapeutic Targets for High-Risk Thyroid Cancer.
    Zhu X; Hu C; Zhang Z; Zhu Y; Liu W; Zheng B; Feng X; Lu H
    Endocr Pathol; 2024 Sep; 35(3):230-244. PubMed ID: 39102163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 expression in papillary thyroid cancer with and without lymphocytic thyroiditis: a cross sectional study.
    Fadia M; Fookeerah P; Ali S; Shadbolt B; Greenaway T; Perampalam S
    Pathology; 2020 Apr; 52(3):318-322. PubMed ID: 32107082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CKS1B promotes cell proliferation and invasion by activating STAT3/PD-L1 and phosphorylation of Akt signaling in papillary thyroid carcinoma.
    Wang H; Zhang Z; Yan Z; Ma S
    J Clin Lab Anal; 2021 Jan; 35(1):e23565. PubMed ID: 32960462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis.
    Zhu C; Dai Y; Zhang H; Ruan Y; Zhou Y; Dai Y; Fan L; Jia T; Lu H; Chen Q
    Diagn Pathol; 2021 Aug; 16(1):84. PubMed ID: 34465342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Lymphocytic Thyroiditis with Oncocytic Metaplasia Influences PD-L1 Expression in Papillary Thyroid Carcinoma.
    Santana VB; Krüger VM; Abrahão MCY; Cantú PLM; Brackmann RL; Pandolfi GM; Marisco LS; Remonatto G; Ferreira LA; Graudenz MS
    Head Neck Pathol; 2024 Mar; 18(1):14. PubMed ID: 38457034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PROGRAMMED CELL DEATH-LIGAND 1 OVEREXPRESSION IN THYROID CANCER.
    Zhang GQ; Wei WJ; Song HJ; Sun ZK; Shen CT; Zhang XY; Chen XY; Qiu ZL; Luo QY
    Endocr Pract; 2019 Mar; 25(3):279-286. PubMed ID: 30913016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 and MCL-1 markers and the relationship with prognostic characteristics of differentiated thyroid carcinoma.
    Zantut-Wittmann DE; Barreto IS; Laus AC; Moreno DA; Moma CA; Maia FFR; Assumpção LVMD; Reis RM
    Mol Cell Endocrinol; 2023 Jun; 570():111931. PubMed ID: 37072108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 and PD-1 expression in thyroid follicular epithelial dysplasia: Hashimoto thyroiditis related atypia and potential papillary carcinoma precursor.
    Pakkanen E; Kalfert D; Ahtiainen M; Ludvíková M; Kuopio T; Kholová I
    APMIS; 2022 May; 130(5):276-283. PubMed ID: 35238073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of Programmed Death 1 Inhibited Progression of Papillary Thyroid Carcinoma in Mice.
    Wang H; Chu Q; Ma S; Tao Y
    Protein Pept Lett; 2023; 30(5):396-400. PubMed ID: 36876839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coexistence of chronic lymphocytic thyroiditis and papillary thyroid carcinoma. Impact on presentation, management, and outcome.
    Dobrinja C; Makovac P; Pastoricchio M; Cipolat Mis T; Bernardi S; Fabris B; Piscopello L; de Manzini N
    Int J Surg; 2016 Apr; 28 Suppl 1():S70-4. PubMed ID: 26708864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 and thyroid cytology: A possible diagnostic and prognostic marker.
    Dell'Aquila M; Granitto A; Martini M; Capodimonti S; Cocomazzi A; Musarra T; Fiorentino V; Pontecorvi A; Lombardi CP; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
    Cancer Cytopathol; 2020 Mar; 128(3):177-189. PubMed ID: 31821747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
    Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
    Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.